Novartis Pharma accused over drug ads

Novartis Pharma accused over drug ads

TOKYO, Japan - Health, Labor and Welfare Ministry officials hold a press conference at the ministry in Tokyo on Jan. 9, 2014, after filing a criminal complaint with prosecutors against Novartis Pharma K.K. over alleged exaggerated advertising for a blood pressure-lowering drug.

  • Product Code
  • ILEA001190870
  • Registered date
  • 2014/1/09 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2014 Kyodo News
  • Media size
  • 1694 × 1046 pixel
  • Resolution
  • 240 dpi
  • Deployment size
  • 235.48(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Entrance ceremony for new ministry officials

    Entrance ceremony for new ministry officials

    New recruits at the Ministry of Health, Labor and Welfare attend an entrance ceremony at the ministry in Tokyo on April 1, 2024, the first day of the new business year. (Pool photo)
      BOJ chief Ueda after policy-setting meeting

      BOJ chief Ueda after policy-setting meeting

      Bank of Japan Governor Kazuo Ueda speaks during a press conference at the central bank's headquarters in Tokyo on Jan. 23, 2024, after its two-day policy-setting meeting.
        JAL taps Tottori as 1st female president

        JAL taps Tottori as 1st female president

        Japan Airlines Co. President Yuji Akasaka (L) and senior managing executive officer Mitsuko Tottori, a former flight attendant, shake hands at a press conference in Tokyo on Jan. 17, 2024. Tottori was named to become the company's first female president in April.
          JAL president Akasaka

          JAL president Akasaka

          Japan Airlines Co. President Yuji Akasaka speaks at a press conference in Tokyo on Jan. 17, 2024.
            Keidanren chairman Tokura

            Keidanren chairman Tokura

            Masakazu Tokura, chairman of the Japan Business Federation, also known as Keidanren, holds a press conference in Tokyo on Jan. 9, 2024.
              New Year meeting of major business lobbies

              New Year meeting of major business lobbies

              Ken Kobayashi, chairman of the Japan Chamber of Commerce and Industry, holds a press conference after attending a New Year meeting hosted by Japan's three major business organizations in Tokyo on Jan. 5, 2024.
                Head of Japan's most influential business lobby

                Head of Japan's most influential business lobby

                Masakazu Tokura, chairman of the Japan Business Federation, known as Keidanren, speaks at a press conference in Tokyo on Jan. 23, 2023.
                  U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                  U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                  Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
                    U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                    U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                    Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
                      U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                      U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                      Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.